Market Research Life Sciences Market Research Pharmaceuticals Market Research Therapeutic Area Market Research CNS/Neurology Market Research

Dementia Associated with Alzheimer's Disease Market (Drug Class: Cholinergic/Cholinesterase Inhibitors, Memantine, Combined Drugs, Others; Distribution Channel: Hospital Pharmacies, Retail, Online Sales) - Global Industry Analysis, Size, Share, Growth, Tr

Best Price Guarantee Length Publisher Published Date SKU
from $5,795 172 Pages Transparency Market Research Pvt. Ltd. January, 2024 TNPR18580357
Best Price Guarantee
Price from $5,795
Length 172 Pages
Publisher Transparency Market Research Pvt. Ltd.
Published Date January, 2024
SKU TNPR18580357

Dementia Associated with Alzheimer's Disease Market (Drug Class: Cholinergic/Cholinesterase Inhibitors, Memantine, Combined Drugs, Others; Distribution Channel: Hospital Pharmacies, Retail, Online Sales) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2023-2031


Dementia Associated with Alzheimer's Disease Market – Scope of Report

TMR’s report on the global dementia associated with Alzheimer’s disease market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global dementia associated with Alzheimer’s disease market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global dementia associated with Alzheimer’s disease market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the dementia associated with Alzheimer’s disease market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global dementia associated with Alzheimer’s disease market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global dementia associated with Alzheimer’s disease market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global dementia associated with Alzheimer’s disease market.

The report delves into the competitive landscape of the global dementia associated with Alzheimer’s disease market. Key players operating in the global dementia associated with Alzheimer’s disease market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global dementia associated with Alzheimer’s disease market profiled in this report.

Key Questions Answered in Global dementia associated with Alzheimer’s disease Market Report
  • What is the sales/revenue generated by dementia associated with Alzheimer’s disease across all regions during the forecast period?
  • What are the opportunities in the global dementia associated with Alzheimer’s disease market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Dementia Associated with Alzheimer's Disease Market – Research Objectives and Research Approach

The comprehensive report on the global dementia associated with Alzheimer’s disease market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global dementia associated with Alzheimer’s disease market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global dementia associated with Alzheimer’s disease market.


1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Dementia Associated with Alzheimer’s Disease Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Dementia Associated with Alzheimer’s Disease Market Analysis and Forecasts, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Disease Prevalence & Incidence Rate Globally With Key Countries
5.3. COVID-19 Pandemic Impact on Industry
6. Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast, by Drug Class
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2017–2031
6.3.1. Cholinergic/Cholinesterase (ChE) Inhibitors
6.3.2. Memantine
6.3.3. Combined Drugs (Memantine & Donepezil)
6.3.4. Others
6.4. Market Attractiveness, by Drug Class
7. Global Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast, by Distribution Channel
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Distribution Channel, 2017–2031
7.3.1. Hospital Pharmacies
7.3.2. Retail
7.3.3. Online Sales
7.4. Market Attractiveness, by Distribution Channel
8. Global Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2017–2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
9. North America Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Drug Class, 2017–2031
9.2.1. Cholinergic/Cholinesterase (ChE) Inhibitors
9.2.2. Memantine
9.2.3. Combined Drugs (Memantine & Donepezil)
9.2.4. Others
9.3. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.1. Hospital Pharmacies
9.3.2. Retail
9.3.3. Online Sales
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017–2031
10.2.1. Cholinergic/Cholinesterase (ChE) Inhibitors
10.2.2. Memantine
10.2.3. Combined Drugs (Memantine & Donepezil)
10.2.4. Others
10.3. Market Value Forecast, by Distribution Channel, 2017–2031
10.3.1. Hospital Pharmacies
10.3.2. Retail
10.3.3. Online Sales
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017–2031
11.2.1. Cholinergic/Cholinesterase (ChE) Inhibitors
11.2.2. Memantine
11.2.3. Combined Drugs (Memantine & Donepezil)
11.2.4. Others
11.3. Market Value Forecast, by Distribution Channel, 2017–2031
11.3.1. Hospital Pharmacies
11.3.2. Retail
11.3.3. Online Sales
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017–2031
12.2.1. Cholinergic/Cholinesterase (ChE) Inhibitors
12.2.2. Memantine
12.2.3. Combined Drugs (Memantine & Donepezil)
12.2.4. Others
12.3. Market Value Forecast, by Distribution Channel, 2017–2031
12.3.1. Hospital Pharmacies
12.3.2. Retail
12.3.3. Online Sales
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017–2031
13.2.1. Cholinergic/Cholinesterase (ChE) Inhibitors
13.2.2. Memantine
13.2.3. Combined Drugs (Memantine & Donepezil)
13.2.4. Others
13.3. Market Value Forecast, by Distribution Channel, 2017–2031
13.3.1. Hospital Pharmacies
13.3.2. Retail
13.3.3. Online Sales
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Merz Pharma
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Novartis AG
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. AbbVie Inc.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Pfizer, Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Daiichi Sankyo Company, Limited.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Ono Pharmaceutical Co., Ltd.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Johnson & Johnson Services, Inc.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. Financial Overview
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Eisai Co., Ltd.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. Financial Overview
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. H. Lundbeck A/S
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. Financial Overview
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. F. Hoffmann-La Roche Ltd.
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Product Portfolio
14.3.10.3. Financial Overview
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview

$5,795
$8,795
$11,795

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings